{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Apixaban+alone",
    "query": {
      "intervention": "Apixaban alone"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Apixaban+alone&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T01:55:47.599Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03251482",
      "title": "A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery"
      ],
      "interventions": [
        {
          "name": "JNJ-64179375 0.3 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 0.6 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 1.2 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 (Dose to be Determined)",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 A mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 B mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 C mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 D mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo JNJ-64179375",
          "type": "DRUG"
        },
        {
          "name": "Apixaban placebo",
          "type": "DRUG"
        },
        {
          "name": "Apixaban 2.5 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 308,
      "start_date": "2017-11-13",
      "completion_date": "2018-11-05",
      "has_results": true,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-09-06T01:55:47.599Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03251482"
    },
    {
      "nct_id": "NCT03083782",
      "title": "Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Pharmacokinetics",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Apixaban alone",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2017-04-18",
      "completion_date": "2017-06-30",
      "has_results": false,
      "last_update_posted_date": "2017-10-11",
      "last_synced_at": "2026-09-06T01:55:47.599Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03083782"
    },
    {
      "nct_id": "NCT04895553",
      "title": "Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioma, Malignant"
      ],
      "interventions": [
        {
          "name": "Observation of ICH and VTE",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-08-01",
      "completion_date": "2022-08-05",
      "has_results": false,
      "last_update_posted_date": "2022-12-02",
      "last_synced_at": "2026-09-06T01:55:47.599Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04895553"
    },
    {
      "nct_id": "NCT01340586",
      "title": "Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2011-06",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2016-10-11",
      "last_synced_at": "2026-09-06T01:55:47.599Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01340586"
    },
    {
      "nct_id": "NCT05701917",
      "title": "DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Deep Venous Thrombosis",
        "Post-Thrombotic Syndrome"
      ],
      "interventions": [
        {
          "name": "ClotTriever System",
          "type": "DEVICE"
        },
        {
          "name": "Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Inari Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2023-01-06",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-09-06T01:55:47.599Z",
      "location_count": 48,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05701917"
    },
    {
      "nct_id": "NCT03288454",
      "title": "Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ciraparantag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-08-30",
      "completion_date": "2019-08-05",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-09-06T01:55:47.599Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03288454"
    },
    {
      "nct_id": "NCT06055920",
      "title": "The PEERLESS II Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "FlowTriever System",
          "type": "DEVICE"
        },
        {
          "name": "Anticoagulation Agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Inari Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1200,
      "start_date": "2023-11-17",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-06T01:55:47.599Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06055920"
    },
    {
      "nct_id": "NCT02599532",
      "title": "Pharmacokinetics of Apixaban in Nephrotic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nephrotic Syndrome",
        "Proteinuria"
      ],
      "interventions": [
        {
          "name": "apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 21,
      "start_date": "2017-04-30",
      "completion_date": "2019-06-28",
      "has_results": false,
      "last_update_posted_date": "2019-07-24",
      "last_synced_at": "2026-09-06T01:55:47.599Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02599532"
    },
    {
      "nct_id": "NCT03864406",
      "title": "Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Cobicistat",
          "type": "DRUG"
        },
        {
          "name": "Darunavir/Cobicistat",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2019-06-04",
      "completion_date": "2022-12-10",
      "has_results": true,
      "last_update_posted_date": "2023-12-01",
      "last_synced_at": "2026-09-06T01:55:47.599Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03864406"
    },
    {
      "nct_id": "NCT03509883",
      "title": "Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Drug: Apixaban sprinkle capsules",
          "type": "DRUG"
        },
        {
          "name": "Experimental: Apixaban tablets followed by apixaban sprinkle capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 94,
      "start_date": "2018-04-26",
      "completion_date": "2018-06-15",
      "has_results": true,
      "last_update_posted_date": "2020-01-23",
      "last_synced_at": "2026-09-06T01:55:47.599Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03509883"
    }
  ]
}